Advertisement
Organisation › Details
Xbrane (Group)
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product candidate XlucaneTM is a biosimilar on the original drug Lucentis®, a VEGFa inhibitor used in the treatment of a number of severe eye diseases. A global pivotal phase III study is ongoing for XlucaneTM and launch of the product is expected second half of 2022. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. *
Start | 2015-10-17 existent | |
Industry | DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics) | |
Industry 2 | biopharmaceutical production technology | |
Person | Åmark, Martin (Xbrane 2020 CEO9 | |
Person 2 | Lindquist, Anette (Xbrane 2020 CFO + IR) | |
Region | Stockholm | |
Country | Sweden | |
Street | 15 Stureplan | |
City | 11145 Stockholm | |
Tel | +46-734-343619 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2020-12-31) |
Currency | SEK | |
Profit | -226,026,000 (2020-12-31) | |
Cash | 243,139,000 (2020-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top